Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Presentation to Annual General Meeting

Monday, November 25, 2024 1 min read
Key Takeaway: Radiopharm Theranostics is set to present at its Annual General Meeting on November 25, 2024. The company has recently made significant progress, including the dosing of the first patient in its Phase 1/2a clinical study of BetaBart (RV-01) and receiving IND approval from the US FDA. These developments reflect the company's commitment to advancing its clinical programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA.
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Investor Presentations
• November 25, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• November 11, 2022
• Announcements
• June 25, 2024
• Announcements
• October 26, 2022
• Announcements
• February 5, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the date of the Annual General Meeting?

The Annual General Meeting is scheduled for November 25, 2024.

What clinical study did Radiopharm initiate?

Radiopharm initiated a Phase 1/2a clinical study of BetaBart (RV-01).

What recent approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA for its therapeutic study.

How many clinical programs received updates?

Radiopharm provided positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a IND approval clinical study
Last updated: Nov 25, 2024